DnB Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $17.4M | Buy |
|
|||||
|
2025
Q2 | $14.4M | Sell |
|
|||||
|
2025
Q1 | $14.2M | Buy |
|
|||||
|
2024
Q4 | $16.1M | Buy |
|
|||||
|
2024
Q3 | $13.2M | Buy |
|
|||||
|
2024
Q2 | $10.3M | Buy |
|
|||||
|
2024
Q1 | $8.82M | Sell |
|
|||||
|
2023
Q4 | $8.68M | Sell |
|
|||||
|
2023
Q3 | $9M | Sell |
|
|||||
|
2023
Q2 | $7.89M | Sell |
|
|||||
|
2023
Q1 | $9.73M | Buy |
|
|||||
|
2022
Q4 | $10.4M | Sell |
|
|||||
|
2022
Q3 | $9.32M | Sell |
|
|||||
|
2022
Q2 | $12.3M | Sell |
|
|||||
|
2022
Q1 | $12.7M | Sell |
|
|||||
|
2021
Q4 | $12M | Buy |
|
|||||
|
2021
Q3 | $11.3M | Sell |
|
|||||
|
2021
Q2 | $13.5M | Buy |
|
|||||
|
2021
Q1 | $11.6M | Buy |
|
|||||
|
2020
Q4 | $3.37M | Buy |
|
|||||
|
2020
Q3 | $1.19M | Hold |
|
|||||
|
2020
Q2 | $1.51M | Buy |
|
|||||
|
2020
Q1 | $943K | Sell |
|
|||||
|
2019
Q4 | $1.27M | Buy |
|